1. An active energy ray-curable ink composition comprising a coloring agent, a binder resin, and a radically polymerizable varnish andor a radically polymerizable monomer as main components; wherein said coloring agent is a modified pigment obtained by polymerization, wherein a pigment (A), a nonaqueous solvent and an acrylic resin (B-1) containing a polymerizable unsaturated group are mixed to form a mixture, and at least one kind of polymerizable unsaturated monomer (C), which is a multifunctional polymerizable unsaturated monomer, is further mixed to the mixture to form a polymer on the pigment (A), wherein the polymer is obtained by cross-linking between the acrylic resin (B-1) and the multifunctional polymerizable unsaturated monomer, or cross-linking between the acrylic resin (B-1) and a polymer generated by polymerization of the multifunctional polymerizable unsaturated monomer.
2. The active energy ray-curable ink composition according to claim 1, wherein the acrylic resin (B-1) is a polymer which is formed by introducing a polymerizable unsaturated group to a copolymer of polymerizable unsaturated monomers which have, as a main component, alkyl (meth)acrylate having an alkyl group which has four or more carbon atoms; or
a macromonomer which is a copolymer of polymerizable unsaturated monomers which have, as a main component, alkyl (meth)acrylate having an alkyl group which has four or more carbon atoms.
3. The active energy ray-curable ink composition according to claim 1, wherein the nonaqueous solvent includes an aliphatic solvent andor an alicyclic hydrocarbonic solvent.
4. A printed matter which has a coating film obtained by curing and drying the active energy ray-curable ink composition according to claim 1.
5. The active energy ray-curable ink composition according to claim 2, wherein the nonaqueous solvent includes an aliphatic solvent andor an alicyclic hydrocarbonic solvent.
6. A printed matter which has a coating film obtained by curing and drying the active energy ray-curable ink composition according to claim 2.
7. The active energy ray-curable ink composition according to claim 1, wherein the polymer (B) is soluble in the nonaqueous solvent.
8. The active energy ray-curable ink composition according to claim 1, wherein the monomer (C) is originally soluble in the nonaqueous solvent but becomes insoluble or poorly soluble after polymerization thereof.
9. The active energy ray-curable ink composition according to claim 1, wherein the pigment (A), on which the polymer is formed, is dried to form the modified pigment.
10. The active energy ray-curable ink composition according to claim 1, wherein cross-linking between the acrylic resin (B-1) and the multifunctional polymerizable unsaturated monomer or cross-linking between the acrylic resin (B-1) and a polymer generated by polymerization of the multifunctional polymerizable unsaturated monomer is performed at a temperature in a range of 60 to 130\xb0 C.
11. The active energy ray-curable ink composition according to claim 1, wherein the amount of the polymer formed on the pigment is from 2 to 400 parts per 100 parts of the pigment (A).
12. The active energy ray-curable ink composition according to claim 1, wherein the ink composition include 5 to 50% by mass of the binder resin, and 20 to 90% by mass of both of or one of the radical polymerizable varnish and the radical polymerizable monomer.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
Therefore, we claim:
1. A compound represented by the structural formula (I):
53
or pharmaceutically acceptable isomers, salts, solvates or esters of the compound of Formula (i),
wherein in Formula (I) above:
X, Y and Z can be the same or different and each is independently selected from the group consisting of CH2, CH(alkyl)- and C(alkyl)2;
Q1 and Q2 can be the same or different and each is independently selected from the group consisting of H, (C0-C30 alkylene)-G, OR6, OC(O)R6, OC(O)OR9, OC(O)NR6R7, and -L-M;
Q3 is 1 to 5 substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, (C0-C30 alkylene)-G, (C0-C10 alkylene)-OR6, (C0-C10 alkylene)-C(O)R6, (C0-C10 alkylene)-C(O)OR6, (C0-C10 alkylene)-OC(O)R6, (C0-C10 alkylene)-OC(O)OR9, CHCHC(O)R6, CHCHC(O)OR6, CCC(O)OR6, CCC(O)R6, O(C1-C10 alkylene)-OR6, O(C1-C10 alkylene)-C(O)R6, O(C1-C10 alkylene)-C(O)OR6, CN, O(C1-C10 alkylene)-C(O)NR6R7, O(C0-C10 alkylene)-C(O)NR6NR7C(O)OR6, O(C1-C10 alkylene)-C(O)(aryl)-NNN, OC(O)(C1-C10 alkylene)-C(O)OR6, (C0-C10 alkylene)-C(O)NR6R7, (C0-C10 alkylene)-OC(O)NR6R7, NO2, (C0-C10 alkylene)-NR6R7, O(C2-C10 alkylene)-NR6R7, NR6C(O)R7, NR6C(O)OR9, NR6C(O)NR7R8, NR6S(O)0-2R9, N(S(O)0-2R9)2, CHNOR6, C(O)NR6R7, C(O)NR6NR6R7, S(O)0-2NR6R7, S(O)0-2R9, OC(O)(C1-C10 alkylene)-C(O)NR6R7, OC(O)(C1-C10 alkylene)-NR6C(O)O-(alkylaryl), P(O)(OR10)2, (C1-C10 alkylene)-OSi(alkyl)3, CF3, OCF3, halo, alkoxyalkoxy, alkoxyalkoxyalkoxy, alkoxycarbonylalkoxy, alkoxyarylalkoxy, alkoxyiminoalkyl, alkyidioyl, allyloxy, aryl, arylalkyl, aryloxy, arylalkoxy, aroyl, aroyloxy, aroylaroyloxy, arylalkoxycarbonyl, benzoylbenzoyloxy, heteroaryl, heteroarylalkyl, heteroarylalkoxy, dioxolanyl, heterocyclyl, heterocyclylalkyl, heterocyclylcarbonyl, heterocyclylcarbonylalkoxy and -L-M;
Q4 is 1 to 5 substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, (C0-C30 alkylene)-G, (C0-C10 alkylene)-OR6, (C0-C10 alkylene)-C(O)R6, (C0-C10 alkylene)-C(O)OR6, (C0-C10 alkylene)-OC(O)R6, (C0-C10 alkylene)-OC(O)OR9, CHCHC(O)R6, CHCHC(O)OR6, CCC(O)OR6, CCC(O)R6, O(C1-C10 alkylene)-OR6, O(C1-C10 alkylene)-C(O)R6, O(C1-C10 alkylene)-C(O)OR6, CN, O(C1-C10 alkylene)-C(O)NR6R7, O(C0-C10 alkylene)-C(O)NR6NR7C(O)OR6, O(C1-C10 alkylene)-C(O)(aryl)-NNN, OC(O)(C1-C10 alkylene)-C(O)OR6, (C0-C10 alkylene)-C(O)NR6R7, (C0-C10 alkylene)-OC(O)NR6R7, NO2, (C0-C10 alkylene)-NR6R7, O(C2-C10 alkylene)-NR6R7, NR6C(O)R7, NR6C(O)OR9, NR6C(O)NR7R8, NR6S(O)0-2R9, N(S(O)0-2R9)2, CHNOR6, C(O)NR6R7, C(O)NR6NR6R7, S(O)0-2NR6R7, S(O)0-2R9, OC(O)(C1-C10 alkylene)-C(O)NR6R7, OC(O)(C1-C10 alkylene)-NR6C(O)O-(alkylaryl), P(O)(OR10)2, (C1-C10 alkylene)-OSi(alkyl)3, CF3, OCF3, halo, alkoxyalkoxy, alkoxyalkoxyalkoxy, alkoxycarbonylalkoxy, alkoxyarylalkoxy, alkoxyiminoalkyl, alkyldioyl, allyloxy, aryl, arylalkyl, aryloxy, arylalkoxy, aroyl, aroyloxy, aroylaroyloxy, arylalkoxycarbonyl, benzoylbenzoyloxy, heteroaryl, heteroarylalkyl, heteroarylalkoxy, dioxolanyl, heterocyclyl, heterocyclylalkyl, heterocyclylcarbonyl, heterocyclylcarbonylalkoxy and -L-M;
Q5 is 1 to 5 substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, (C0-C30 alkylene)-G, (C0-C10 alkylene)-OR6, (C0-C10 alkylene)-C(O)R6, (C0-C10 alkylene)-C(O)OR6, (C0-C10 alkylene)-OC(O)R6, (C0-C10 alkylene)-OC(O)OR9, CHCHC(O)R6, CHCHC(O)OR6, CCC(O)OR6, CCC(O)R6, O(C1-C10 alkylene)-OR6, O(C1-C10 alkylene)-C(O)R6, O(C1-C10 alkylene)-C(O)OR6, CN, O(C1-C10 alkylene)-C(O)NR6R7, O(C0-C10 alkylene)-C(O)NR6NR7C(O)OR6, O(C1-C10 alkylene)-C(O)(aryl)-NNN, OC(O)(C1-C10 alkylene)-C(O)OR6, (C0-C10 alkylene)-C(O)NR6R7, (C0-C10 alkylene)-OC(O)NR6R7, NO2, (C0-C10 alkylene)-NR6R7, O(C2-C10 alkylene)-NR6R7, NR6C(O)R7, NR6C(O)OR9, NR6C(O)NR7R8, NR6S(O)0-2R9, N(S(O)0-2R9)2, CHNOR6, C(O)NR6R7, C(O)NR6NR6R7, S(O)0-2NR6R7, S(O)0-2R9, OC(O)(C1-C10 alkylene)-C(O)NR6R7, OC(O)(C1-C10 alkylene)-NR6C(O)O-(alkylaryl), P(O)(OR10)2, (C1-C10 alkylene)-OSi(alkyl)3, CF3, OCF3, halo, alkoxyalkoxy, alkoxyalkoxyalkoxy, alkoxycarbonylalkoxy, alkoxyarylalkoxy, aikoxyiniinoalkyl, alkyidioyl, allyloxy, aryl, arylalkyl, aryloxy, arylalkoxy, aroyl, aroyloxy, aroylaroyloxy, arylalkoxycarbonyl, benzoylbenzoyloxy, heteroaryl, heteroarylalkyl, heteroarylalkoxy, dioxolanyl, heterocyclyl, heterocyclylalkyl, heterocyclylcarbonyl, heterocyclylcarbonylalkoxy and -L-M;
wherein optionally one or more carbon atoms of the (C0-C30 alkylene)- radical of Q1, Q2, Q3, Q4 and Q5 is independently replaced by O, C(O), CHCH, CC, N(alkyl)-, N(alkylaryl)- or NH;
G is selected from the group consisting of a sugar residue, disugar residue, trisugar residue, tetrasugar residue, sugar acid, amino sugar, amino acid residue, oligopeptide residue comprising 2 to 9 amino acids, trialkylammoniumalkyl radical and S(O)2OH, wherein optionally the sugar residue, disugar residue, trisugar residue, tetrasugar residue, sugar acid, amino sugar, amino acid residue or oligopeptide residue of G is substituted with -L-M;
L is selected from the group consisting of
54
wherein Me is methyl;
M is selected from the group consisting of
55
56
R1 and R3 can be the same or different and each is independently selected from the group consisting of hydrogen, alkyl and aryl;
R6, R7 and R8 can be the same or different and each is independently selected from the group consisting of hydrogen, alkyl, aryl and arylalkyl; and
each R9 is independently alkyl, aryl or arylalkyl.
each R10 is independently H or alkyl;
q is 0 or 1;
r is 0 or 1;
m, n and p are independently selected from 0, 1, 2, 3 or 4; provided that at least one of q and r is 1, and the sum of m, n, p, q and r is 1, 2, 3, 4, 5 or 6; and provided that when p is 0 and r is 1, the sum of m, q and n is 1, 2, 3, 4 or 5;
x1 is 1 to 10;
x2 is 1 to 10;
x3 is 1 to 10;
x4 is 1 to 10;
x5 is 1 to 10;
x6 is 1 to 10; and
x7 is 1 to 10;
with the proviso that at least one of Q1, Q2, Q3, Q4 and Q5 is -L-M or the sugar residue, disugar residue, trisugar residue, tetrasugar residue, sugar acid, amino sugar, amino acid residue or oligopeptide residue of G is substituted with -L-M.
2. The compound according to claim 1, wherein m, n and r are each zero, q is 1, p is 2, and Z is CH2.
3. The compound according to claim 1, wherein m, n and r are each zero, q is 1, p is 2, and Z is CH2, Q1 is OR6, wherein R6 is hydrogen and Q5 is fluorine.
4. The compound according to claim 1, wherein R2 and R3 are each preferably hydrogen.
5. The compound according to claim 1, wherein Q1 and Q2 are each independently selected from the group consisting of OR6, O(CO)R6, O(CO)OR9 and O(CO)NR6R7.
6. The compound according to claim 1, wherein Q4 is halo or OR6.
7. The compound according to claim 1, wherein Q1 is OR6 wherein R6 is H.
8. The compound according to claim 1, wherein Q1, Q2, Q3, Q4 or Q5 is -L-M.
9. The compound according to claim 1, wherein Q1, Q2, Q3, Q4 or Q5 is (C0-C30 alkylene)-G.
10. The compound according to claim 1, wherein G is selected from the group consisting of:
57
wherein R, Ra and Rb can be the same or different and each is independently selected from the group consisting of H, OH, halo, NH2, azido, alkoxyalkoxy or WR30;
W is independently selected from the group consisting of NHC(O), OC(O), OC(O)N(R31), NHC(O)N(R31) and OC(S)-N(R31);
R2a and R6a can be the same or different and each is independently selected from the group consisting of H, alkyl, acetyl, aryl and arylalkyl;
R3a, R4a, R5a, R7a, R3b and R4b can be the same or different and each is independently selected from the group consisting of H, alkyl, acetyl, arylalkyl, C(O)alkyl and C(O)aryl;
R30 is independently selected from the group consisting of R32-substituted T, R32-substituted-T-alkyl, R32-substituted-alkenyl, R32-substituted-alkyl, R32-substituted-cycloalkyl and R32-substituted-cycloalkylalkyl;
R31 is independently selected from the group consisting of H and alkyl;
T is independently selected from the group consisting of phenyl, furyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, benzothiazolyl, thiadiazolyl, pyrazolyl, imidazolyl and pyridyl;
R32 is 1 to 3 substituents which are each independently selected from the group consisting of H, halo, alkyl, OH, phenoxy, CF3, NO2, alkoxy, methylenedioxy, oxo, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, N(CH3)2, C(O)NHalkyl, C(O)N(alkyl)2, C(O)-alkyl, C(O)-alkoxy and pyrrolidinylcarbonyl; or R32 is a covalent bond and R31, the nitrogen to which it is attached and R32 form a pyrrolidinyl, piperidinyl, N-methyl-piperazinyl, indolinyl or morpholinyl group, or a alkoxycarbonyl-substituted pyrrolidinyl, piperidinyl, N-methylpiperazinyl, indolinyl or morpholinyl group.
11. The compound according to claim 10, wherein G is selected from:
58
wherein Ac is acetyl and Ph is phenyl.
12. The compound according to claim 1, wherein optionally one or more carbon atoms of the (C0-C30 alkylene)- radical of Q1, Q2, Q3, Q4 and Q5 is independently replaced by O.
13. The compound according to claim 1, wherein L is
59
14. The compound according to claim 1, wherein M is
60
15 The compound according to claim 1, wherein M is
61
16. The compound according to claim 1, wherein M is
62
17. The compound according to claim 1, wherein M is
63
18. The compound according to claim 1, wherein M is
64
19. The compound according to claim 1, which is selected from the group consisting of
65
66
67
68
20. A pharmaceutical composition for the treatment or prevention of a vascular condition, diabetes, obesity, stroke, lowering a concentration of a sterol or stanol in plasma of a mammal, preventing demyelination or treating Alzheimer’s disease andor regulating levels of amyloid peptides in a subject comprising a therapeutically effective amount of a compound of claim 1 in a pharmaceutically acceptable carrier.
21. A pharmaceutical composition comprising a cholesterol-lowering effective amount of a compound of claim 1 in a pharmaceutically acceptable carrier.
22. A method of treating or preventing a vascular condition, diabetes, obesity, stroke, lowering a concentration of a sterol or stanol in plasma of a mammal, preventing demyelination or treating Alzheimer’s disease or regulating a level of an amyloid P peptide in a subject comprising the step of administering to a subject in need of such treatment an effective amount of a compound of claim 1.
23. A method of lowering cholesterol level in plasma of a mammal in need of such treatment comprising administering a pharmaceutically effective amount of the compound of claim 1.